menu
    • menu
    [{"orgOrder":0,"company":"National Eye Institute","sponsor":"Nanoscope Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"iVeena","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Copper Sulphate Pentahydrate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"iVeena","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"IVMED-85","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"I27-Breg","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"National Eye Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"National Eye Institute \/ Inapplicable"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Praetego","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"PTG-630","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Synedgen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"2","companyTruncated":"National Eye Institute \/ National Eye Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by National Eye Institute

    Menu

    National Eye Institute

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : RevOpsis Therapeutics

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            RevOpsis Wins $1.8M Grant for Ophthalmic Therapy R&D Advancement

                            Details : The SBIR grant will fund critical R&D activities, including multidose GMP toxicology studies in nonhuman primates for RO-104, a first-in-class fully human modular tri-specific biologic.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : RevOpsis Therapeutics

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVMED-85

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Recipient : iVeena

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            iVeena Awarded NEI-SBIR Grant for Progressive Myopia Drug Candidate IVMED-85

                            Details : The grant will be used for the development of IVMED-85, an investigational eyedrop formulation containing copper intended for treatment of pediatric myopia. IVMED-85 will be the first eye drop inducing both scleral and corneal crosslinking for myopia con...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 26, 2023

                            Lead Product(s) : IVMED-85

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : iVeena

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTG-630

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Praetego

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy

                            Details : Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. PTG-630 has demonstrated remarkable potency as an AGE inhibitor.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : PTG-630

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Praetego

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Trethera

                            Deal Size : $1.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuriti...

                            Details : TRE-515 is a novel first-in-class drug, which has been shown to prevent demyelination, and even facilitate remyelination, in multiple demyelinating disease mouse models. Furthermore, the FDA has designated TRE-515 an Orphan Drug in the treatment of ON.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Trethera

                            Deal Size : $1.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonpiretigene Isteparvovec

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Recipient : Nanoscope Therapeutics

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Nanoscope Awarded $1.5M Phase 2B SBIR Grant to Advance Ambient Light Activatable Opsin Gene Therapy to Restore...

                            Details : Nanoscope’s lead MCO gene therapy, MCO-010, is in a late-stage Phase 2b trial for retinitis pigmentosa (RP) in the US. MCO-010 has orphan drug designations for RP and Stargardt disease from the US Food and Drug Administration.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 14, 2021

                            Lead Product(s) : Sonpiretigene Isteparvovec

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Recipient : Nanoscope Therapeutics

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : I27-Breg

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NIH Scientists Discover New B Cell that Tempers Autoimmunity

                            Details : Infusions of purified IL-27 regulatory B cells (I27-Breg ) reduced symptoms in mouse models of multiple sclerosis (MS) and the eye disease autoimmune uveitis. The research suggests the cells may play a role in future human therapies.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 12, 2021

                            Lead Product(s) : I27-Breg

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery

                            Recipient : Synedgen

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Synedgen Receives Supplemental NEI Funding To Identify Lead Development Candidate for Ocular Mustard Gas Injur...

                            Details : Synedgen has developed a new class of glycopolymers with the ability to suppress inflammation, reduce infection, and improve healing at mucosal surfaces. The additional funding provides resources to optimize down-selection to a lead molecule to advance i...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 29, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery

                            Recipient : Synedgen

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Sulphate Pentahydrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Recipient : iVeena

                            Deal Size : Undisclosed

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            IVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development

                            Details : These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 25, 2020

                            Lead Product(s) : Copper Sulphate Pentahydrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : iVeena

                            Deal Size : Undisclosed

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGTC-401

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Recipient : Beacon Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 09, 2015

                            Lead Product(s) : AGTC-401

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Beacon Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV8-scRS

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Recipient : VegaVect, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 17, 2014

                            Lead Product(s) : AAV8-scRS

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Recipient : VegaVect, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth